Acid reflux pharmacological treatments
Pro Research Analysisby 
Searched over 200M research papers
Proton Pump Inhibitors (PPIs) as First-Line Acid Reflux Treatment
Proton pump inhibitors (PPIs) are the most widely used and effective drugs for treating gastroesophageal reflux disease (GERD) and acid reflux. They work by blocking the H+,K+-ATPase enzyme in the stomach lining, which significantly reduces acid secretion and helps heal esophageal damage caused by acid exposure. PPIs are recommended for both non-erosive reflux disease (NERD) and erosive esophagitis (EE), and are also used for long-term management in patients with Barrett’s esophagus due to their potential chemopreventive effects Scarpignato2020Chapelle2020Hossa2025+2 MORE.
Limitations of PPIs and the Need for Alternative Therapies
Despite their effectiveness, up to 40–55% of patients on daily PPI therapy continue to experience symptoms, a condition known as PPI-refractory GERD. PPIs have limitations such as slow onset of action, short half-life, and variable efficacy due to genetic differences in metabolism. These limitations have driven the search for new pharmacological options that can provide faster, more consistent, and longer-lasting acid suppression Scarpignato2020Vakil2004Chapelle2020+4 MORE.
Potassium-Competitive Acid Blockers (P-CABs): A New Generation
Potassium-competitive acid blockers (P-CABs), such as vonoprazan, tegoprazan, fexuprazan, and keverprazan, represent a newer class of acid-suppressing drugs. P-CABs offer rapid, potent, and prolonged acid inhibition from the first dose, overcoming many drawbacks of PPIs. They have shown at least similar, and sometimes superior, efficacy compared to PPIs, especially in patients with severe esophagitis or those who do not respond to PPIs. P-CABs also have a favorable safety profile in short-term use, but more data are needed for long-term safety Scarpignato2020Chapelle2020Hossa2025+2 MORE.
Antacids and Alginates: Over-the-Counter and Symptom Relief Options
Antacids and alginate-based formulations are commonly used for immediate symptom relief in mild GERD and are available over the counter. They work by neutralizing stomach acid and forming a protective barrier to prevent acid from reaching the esophagus. These agents are especially useful for self-management and are recommended as first-line therapy for heartburn, including during pregnancy Mazumder2023Garg2022.
Histamine-2 Receptor Antagonists (H2RAs) and Other Agents
Histamine-2 receptor antagonists (H2RAs) are another class of drugs that reduce acid secretion, though they are generally less effective than PPIs and P-CABs. They may be used in combination with other agents for added benefit. Other pharmacological options include prokinetic agents, which enhance gastrointestinal motility, and receptor-specific drugs targeting pathways involved in reflux, but these are typically reserved for specific cases due to limited efficacy or side effects Vakil2004Mazumder2023Hossa2025+1 MORE.
Combination Therapies and Novel Approaches
Combining medications, such as antacids with alginates or PPIs with prokinetics, can improve symptom control and reduce side effects. New therapeutic avenues are also being explored, including drugs that protect the esophageal mucosa and agents that target transient lower esophageal sphincter relaxations, though many of these are still under investigation Scarpignato2020Vakil2004Mazumder2023+2 MORE.
Conclusion
Pharmacological treatment of acid reflux and GERD is centered on acid suppression, with PPIs as the mainstay and P-CABs emerging as promising alternatives for patients with persistent symptoms. Antacids and alginates remain important for immediate relief and self-care. While current therapies are effective for many, ongoing research into novel agents and combination strategies aims to address unmet needs and improve outcomes for all patients with acid reflux Scarpignato2020Vakil2004Mazumder2023+7 MORE.
Sources and full results
Most relevant research papers on this topic